Malignant Melanoma | Current Treatment: Physician Insights | EU5 | 2016
Malignant melanoma requires a multidisciplinary treatment approach that incorporates surgery, radiotherapy, immunotherapy, and small molecule-targeted therapies. Treatment decisions are influenced by disease stage, resectability, and in the unresectable or metastatic setting, BRAF-mutation status. The malignant melanoma landscape has transformed since 2011: CTLA-4 inhibitors, PD-1 inhibitors, and BRAF/MEK inhibitors are now key treatment options for unresectable disease while adjuvant cytokine therapy remains the mainstay for early-stage disease. This analysis provides insight on current use of approved therapies for malignant melanoma in the EU5 and on factors driving physicians’ prescribing decisions.
Related Market Assessment Reports
Report
Venous Thromboembolism – Current Treatment – Treatment Algorithms: Claims Data Analysis – Venous Thromboembolism (US)
Venous thromboembolism (VTE) is the obstruction of a vein caused by a thrombus, described as deep vein thrombosis (DVT) or pulmonary embolism (PE), depending on the vein affected. Anticoagulants…
Report
Attention-Deficit-Hyperactivity Disorder – Current Treatment – Treatment Algorithms: Claims Data Analysis – Adult ADHD (US)
Attention-deficit / hyperactivity disorder (ADHD), a common childhood neurodevelopmental condition that can persist into adulthood, affects about 6% of U.S. adults, or approximately 15.5 million…
Report
Hyperkalemia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hyperkalemia (US)
Hyperkalemia is defined as a serum potassium level above 5.0 mEq/L. This report covers the management of chronic hyperkalemia through diuretic therapy, correcting metabolic acidosis when present,…
Report
Acute Coronary Syndrome – Current Treatment – Treatment Algorithms: Claims Data Analysis – Acute Coronary Syndrome: Secondary Prevention (US)
Acute coronary syndrome (ACS) is an umbrella term encompassing myocardial infarction and unstable angina. This report focuses on the secondary prevention of ACS (post-ACS), aimed at preventing…
